Anixa Reports First Stable Disease in Phase 1 Ovarian Cancer CAR-T Trial

Source excerpt

Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial News provided by Anixa Biosciences, Inc. Oct 05, 2026, 08:15 ET Share this article Share to X Share this article Share to X First patient in current dose cohort exhibited no progression of her cancer three months after treatment Multiple patients have survived more than one year, including one beyond two years No dose-limiting toxicities observed to date SAN JOSE, Calif. , Oct. 5, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer, today announced that a patient in its ongoing Phase 1, dose-escalating, clinical trial evaluating its novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer, exhibited stable disease 90 days after treatment. This represents the first such response in Anixa's CAR-T cell therapy trial. Correlative studies evaluating presence and durability of CAR positive cells are ongoing. The patient was treated in the fifth dose cohort and received a dose of 1×10⁷ CAR-positive cells per kilogram of body weight following lymphodepletion, representing the highest dose level evaluated to date in the study. To date, no dose-limiting toxicities have been observed in any patients. The Phase 1 study is evaluating lira

Company press release

More on this asset

Oct 1, 2026

08:35 PM

ANIXAnixa Biosciences

Anixa treats second patient in Cohort 5 of FSHR CAR-T ovarian cancer trial

Trial registry changeCompany press release